

Autoimmune congenital heart block (neonatal lupus)

Condition for which IVIg use is in exceptional circumstances only

Specific Conditions

- Autoimmune congenital heart block

Level of Evidence

Insufficient data (Category 4a)

Intravenous immunoglobulin (IVIg) therapy may be indicated during pregnancy when there is a history of autoimmune congenital heart block in at least one previous pregnancy, and maternal SS-A and/or SS-B antibodies are present.

Refer to the current product information sheet for further information.

The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient.

Bibliography

Buyon, JP, Kim, MY, Copel, JA, et al 2001, 'Anti-Ro/SSA antibodies and congenital heart block: necessary but not sufficient', *Arthritis & Rheumatism*, vol. 44, no. 8, pp. 1723–7.

Kaaja, R & Julkunen, H 2003, 'Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: comment on the editorial by Buyon et al', *Arthritis & Rheumatism*, vol. 48, no. 1, pp. 280–1.

Tran, HB, Cavill, D, Buyon, JP, et al 2004, 'Intravenous immunoglobulin and placental transport of anti-Ro/La antibodies: comment on the letter by Kaaja and Julkunen', *Arthritis & Rheumatism*, vol. 50, no. 1, pp. 337–8.

Villain, E, Coatedoat-Chalumeau, N, Marijon, E, et al 2006, 'Presentation and prognosis of complete atrioventricular block in childhood, according to maternal antibody status', *Journal of the American College of Cardiology*, vol. 48, no. 8, pp. 1682–7.

Wong, JP, Kwek, KY, Tan, JY, et al 2001, 'Fetal congenital complete heart block: prophylaxis with intravenous gammaglobulin and treatment with dexamethasone', *Australia New Zealand Journal of Obstetrics and Gynaecology*, vol. 41, no. 3, pp. 339–41.

Generated on: 31 March 2019